Hypertension-related stroke prevention in the elderly

Current Hypertension Reports

Volumn 15, Issue 6, 2013, Pages 582-589

  Aronow, Wilbert S ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

Antihypertensive drug therapy Cardiovascular events; Diuretics; Elderly; Hypertension; Stroke

Indexed keywords

AMILORIDE PLUS HYDROCHLOROTHIAZIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BENDROFLUMETHIAZIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; FELODIPINE; HYDROCHLOROTHIAZIDE; HYDROCHLOROTHIAZIDE PLUS TRIAMTERENE; INDAPAMIDE; ISRADIPINE; LISINOPRIL; METHYLDOPA; METOPROLOL; NITRENDIPINE; PERINDOPRIL; PINDOLOL; PLACEBO; RAMIPRIL; RESERPINE; TELMISARTAN;

ARTICLE; BLOOD PRESSURE; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CORONARY ARTERY DISEASE; DIET; DRUG EFFECT; HIGH RISK POPULATION; HUMAN; HYPERTENSION; LIFESTYLE MODIFICATION; PHYSICAL ACTIVITY; RISK REDUCTION; SMOKING CESSATION; SODIUM RESTRICTION; SYSTOLIC HYPERTENSION; WEIGHT REDUCTION;

AGED; AGING; ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BLOOD PRESSURE DETERMINATION; HUMANS; HYPERTENSION; STROKE;

EID: 84890124507     PISSN: 15226417     EISSN: 15343111     Source Type: Journal    
DOI: 10.1007/s11906-013-0384-x     Document Type: Article

References (59)

1. Kannel WB. Hypertension in the elderly: Epidemiologic appraisal from the Framingham study. Cardiol in Elderly. 1993;1:359-63.
2. Garland C, Barrett-Connor E, Suarez L, Criqui MH. Isolated systolic hypertension and mortality after age 60 years. Am J Epidemiol. 1983;118:365-76.
3. Aronow WS, Ahn C, Gutstein H. Risk factors for new atherothrombotic brain infarction in 664 older men and 1,488 older women. Am J Cardiol. 1996;77:1381-3.
4. Aronow WS, Ahn C, Kronzon I, Koenigsberg M. Congestive heart failure, coronary events and atherothrombotic brain infarction in elderly blacks and whites with systemic hypertension and with and without echocardiographic and electrocardiographic evidence of left ventricular hypertrophy. Am J Cardiol. 1991;67:295-9.
5. •• Aronow WS, Fleg JL, Pepine CJ, et al. ACCF/AHA 2011 expert consensus document on hypertension in the elderly: A report of the american college of cardiology foundation task force on clinical expert consensus documents. Developed in collaboration with the American Academy of Neurology, American Geriatrics Society, American Society for Preventive Cardiology, American Society of Hypertension, American Society of Nephrology, Association of Black Cardiologists, and European Society of Hypertension. J Am Coll Cardiol. 2011;57:2037-114. This paper is the American College of Cardiology Foundation/American Heart Association consensus document on hypertension in the elderly.
6. Amery A, Birkenhager W, Brixko P, et al. Mortality and morbidity results from the European working party on high blood pressure in the elderly trial. Lancet. 1985;1:1349-54.
7. Coope J, Warrender TS. Randomised trial of treatment of hypertension in elderly patients in primary care. BMJ. 1986;293:1145-51.
8. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the systolic hypertension in the elderly program (SHEP). JAMA. 1991;265:3255-64.
9. Perry Jr HM, Davis BR, Price TR, et al. Effect of treating isolated systolic hypertension on the risk of developing various types and subtypes of stroke. The systolic hypertension in the elderly program (SHEP). JAMA. 2000;284:465-71.
10. Dahlof B, Lindholm LH, Hansson L, et al. Morbidity and mortality in the Swedish trial in Old patients with hypertension (STOP hypertension). Lancet. 1991;338:1281-5.
11. MRC Working Party. Medical research council trial of treatment of hypertension in older adults: Principal results. BMJ. 1992;304:405-12.
12. Staessen JA, Fagard R, Thijs L, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet. 1997;350:757-64.
13. Staessen JA, Thijs L, Gasowski J, et al. Treatment of isolated systolic hypertension in the elderly: Further evidence from the systolic hypertension in Europe (syst-Eur) trial. Am J Cardiol. 1998;82:20R-2R.
14. Liu L, Wang JG, Gong L, et al. Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension. Systolic Hypertension in China (Syst-China) Collaborative Group. J Hypertens. 1998;16:1823-9.
15. Beckett NS, Peters R, Fletcher AE, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008;358:1887-98.
16. Miura K, Nakagawa H, Ohashi Y, et al. Four blood pressure indexes and the risk of stroke and myocardial infarction in Japanese men and women. A meta-analysis of 16 cohort studies. Circulation. 2009;119:1892-8.
17. Lloyd-Jones D, Adams R, Carnethon M, et al. Heart disease and stroke statistics-2009 update: A report from the American heart association statistics committee and stroke statistics subcommittee. Circulation. 2009;119:e21-e181.
18. Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. The JNC 7 report. JAMA. 2003;289:2560-72.
19. Spence JD. Nutritional and metabolic aspects of stroke prevention. Adv Neurol. 2003;92:173-8.
20. Aronow WS. Treatment of systemic hypertension. Am J Cadiovasc Dis. 2012;2:160-70.
21. Webster JL, Dunford EK, Hawkes C, Neal BC. Salt reduction initiatives around the world. J Hypertens. 2011;29:1043-50.
22. Frohlich ED, Susic D. Sodium and its multiorgan targets. Circulation. 2011;124:1882-5.
23. Whelton PK. Urinary sodium and cardiovascular disease risk: Informing guidelines for sodium consumption. JAMA. 2011;306:2262-4.
24. Gueyffier F, Boutitie, Boissel J-P. Effect of antihypertensive drug treatment on cardiovascular outcomes in women and men. A meta-analysis of individual patient data from randomized, controlled trials. Ann Intern Med. 1997;126:761-7.
25. Aronow WS, Frishman WH. Treatment of hypertension and prevention of ischemic stroke. Curr Cardiol reports. 2004;6:124-9.
26. Progress Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001;358:1033-41.
27. Hansson L, Lindholm LH, Ekbom T, et al. Randomised trial of old and new antihypertensive drugs in elderly patients: Cardiovascular mortality and morbidity the Swedish trial in Old patients with hypertension-2 study. Lancet. 1999;354:1751-6.
28. Law MR, Morris JK, Wald NJ. Use of BP lowering drugs in the prevention of cardiovascular disease: Meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009;338:b1665. doi: 10.1136/bmj.b1665.
29. Mancia G, Laurent S, Agabiti-Rosei E, et al. Reappraisal of European guidelines on hypertension management: A European society of hypertension task force document. Blood Press. 2009;18:308-47.
30. Aronow WS. What should the optimal blood pressure goal be in patients with diabetes mellitus or chronic kidney disease? Arch Med Sci. 2012;8:399-402.
31. American Diabetes Association. Standards of medical care for patients with diabetes mellitus. Diabetes Care. 2003;26(1):S33-50.
32. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(1):S1-266.
33. Rosendorff C, Black HR, Cannon CP, et al. Treatment of hypertension in the prevention and management of ischemic heart disease. A scientific statement from the American heart association council for high blood pressure research and the councils on clinical cardiology and epidemiology and prevention. Circulation. 2007;115:2761-88.
34. Aronow WS. Treatment of hypercholesterolemia and hypertension in diabetics with coronary artery disease. Clinical Lipidology. 2012;7:689-95.
35. Zanchetti A, Grassi G, Mancia G. When should antihypertensive drug treatment be initiated and to what levels should systolic blood pressure be lowered? a critical appraisal. J Hypertens. 2009;27:923-34.
36. •• Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guidelines for the management of hypertension of arterial hypertension: The task force for the management of arterial hypertension of the European society of hypertension (ESH) and of the European society of cardiology (ESC). Eur Heart J. 2013;34:2159-219. This paper is the European Society of Hypertension/European Society of Cardiology 2013 guidelines document on management of hypertension.
37. Aronow WS. Hypertension guidelines. Hypertension. 2011;58:347-8.
38. Banach M, Michalska M, Kjeldsen SE, et al. What should be the optimal levels of blood pressure: Does the J-curve phenomenon really exist? Expert Opin Pharmacother. 2011;12:1835-44.
39. Banach M, Aronow WS. Should we have any doubts about hypertension therapy in elderly patients. ACCF/AHA 2011 expert consensus document on hypertension in the elderly. Pol Arch Med Wewn. 2011;121:253-8.
40. Aronow WS, Banach M. Ten most important things to learn from the ACCF/AHA 2011 expert consensus document on hypertension in the elderly. Blood Pressure. 2012;21:3-5.
41. Aronow WS. Ten key points from the American College of Cardiology Foundation/American Heart Association 2011 expert consensus document on hypertension in the elderly. Am J Therap. In press
42. Banach M, Aronow WS. Hypertension therapy in the elderly-do we know the answers to all the questions? The status after publication of the ACCF/AHA 2011 Expert Consensus Document on Hypertension in the Elderly. J Hum Hypertens. 2012;26:641-3.
43. Banach M, Aronow WS. Blood pressure J-curve: Current concepts. Curr Hypertens Rep. 2012;14:556-66.
44. Bangalore S, Qin J, Sloan S, et al. What is the optimal blood pressure in patients after acute coronary syndromes? Relationship of blood pressure and cardiovascular events in the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction (PROVE IT-TIMI) 22 trial. Circulation. 2010;122:2142-51.
45. Cooper-DeHoff RM, Gong Y, Handberg EM, et al. Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. JAMA. 2010;304:61-8.
46. The ACCORD Study Group. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010;362:1575-85.
47. Mancia G, Schumacher H, Redon J, et al. Blood pressure targets recommended by guidelines and incidence of cardiovascular and renal events in the ongoing telmisartan alone and in combination with ramipril global endpoint trial (ONTARGET). Circulation. 2011;124:1727-36.
48. Redon J, Mancia G, Sleight P, et al. Safety and efficacy of low blood pressures among patients with diabetes. Subgroup analyses from the ONTARGET (ONgoing telmisartan alone and in combination with ramipril global endpoint trial). J Am Coll Cardiol. 2012;59:74-83.
49. Upadhyay A, Earley A, Haynes SM, Uhlig K. Systematic review: Blood pressure target in chronic kidney disease and proteinuria as an effect modifier. Ann Intern Med. 2011;154:541-8.
50. Banach M, Bhatia V, Feller MA, et al. Relation of baseline systolic blood pressure and long-term outcomes in ambulatory patients with chronic mild to moderate heart failure. Am J Cardiol. 2011;107:1208-14.
51. •• Ovbiagele B, Diener H-C, Yusuf S, et al. Level of systolic blood pressure within the normal range and risk of recurrent stroke. JAMA. 2011;306:2137-44. This paper discusses in 20,330 patients with a recent non-cardioembolic ischemic stroke the recurrent stroke rates for different blood pressure levels.
52. Ogihara T, Matsuoka H, Rakugi H. Practitioner's trial on the efficacy of antihypertensive treatment in elderly patients with hypertension II (PATE-hypertension II study) in Japan. Geriatr Gerontol Int. 2011;11:414-21.
53. Zhang Y, Zhang X, Liu L, et al. Is a systolic blood pressure target <140 mm Hg indicated in all hypertensives? Subgroup analyses of findings from the randomized FEVER trial. Eur Heart J. 2011;32:1500-8.
54. JATOS Study Group. Principal results of the Japanese trial to assess optimal systolic blood pressure in elderly hypertensive patients (JATOS). Hypertens Res. 2008;31:2115-27.
55. Zanchetti A, Liu L, Mancia G, et al. Stroke in hypertension optimal treatment (SHOT) trial: Protocol and organization (abstract). J Hypertens. 2013;31(A):e255.
56. Barylski M, Malyszko J, Rysz J, et al. Lipids, blood pressure, kidney-what was new in 2011? Arch Med Sci. 2011;7:1055-66.
57. Malyszko J, Bachorzewska-Gajewska H, Malyszko J, et al. Markers of kidney function in the elderly in relation to the new CKD-EPI formula for estimation of glomerular filtration rate. Arch Med Sci. 2011;7:658-64.
58. Banach M. Optimal blood pressure levels in elderly persons in the reasons for geographic and racial differences in stroke (REGARDS) cohort study. Clinical Trial Update Hot Line III session. European Society of Cardiology Annual Congress, Amsterdam 31st August-4th September, 2013.
59. Aronow WS. Editorial commentary on dilemmas in treating hypertension in octogenarians. J Clin Hypertens. 2012;14:665-7.